Finckh, A., Ciurea, A., Brulhart, L., Möller, B., Walker, U. A., Courvoisier, D., . . . Arthritis, o. t. b. o. t. d. o. t. S. C. Q. M. P. f. R. (2010). Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? BMJ Group.
Stile di citazione ChicagoFinckh, A., et al. Which Subgroup of Patients With Rheumatoid Arthritis Benefits From Switching to Rituximab Versus Alternative Anti-tumour Necrosis Factor (TNF) Agents After Previous Failure of an Anti-TNF Agent? BMJ Group, 2010.
Citazione MLAFinckh, A., et al. Which Subgroup of Patients With Rheumatoid Arthritis Benefits From Switching to Rituximab Versus Alternative Anti-tumour Necrosis Factor (TNF) Agents After Previous Failure of an Anti-TNF Agent? BMJ Group, 2010.